A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

20201,799 citationsJournal Articlebronze Open Access

Authors

Philip N. Newsome · University Hospitals Birmingham NHS Foundation Trust

Kristine Buchholtz · University Hospitals Birmingham NHS Foundation Trust

Kenneth Cusi · University Hospitals Birmingham NHS Foundation Trust

Martin Linder · University Hospitals Birmingham NHS Foundation Trust

Takeshi Okanoue · University Hospitals Birmingham NHS Foundation Trust

Vlad Ratziu · University Hospitals Birmingham NHS Foundation Trust

Abstract

This phase 2 trial involving patients with NASH showed that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution than placebo. However, the trial did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT02970942.).

Topics & Keywords

Liver Disease Diagnosis and Treatment Metabolism, Diabetes, and Cancer Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 12, pp. 1113-1124

DOI: 10.1056/nejmoa2028395

Field-Weighted Citation Impact: 118.93